The importance of our novel observation that high RelB levels occur in a subset of CLL patients is extended by the observation that high RelB levels were associated with a shorter time to treatment as well as a shorter median OS in CLL. The gene discussed is RELB; the disease is B-cell chronic lymphocytic leukemia.